1 / 20

Modeling bacterial phenotypes using conditional knockdown mutants

Modeling bacterial phenotypes using conditional knockdown mutants. Dirk Schnappinger, PhD Weill Cornell Medical College. Target-based antibacterial drug discovery has been difficult.

clay
Télécharger la présentation

Modeling bacterial phenotypes using conditional knockdown mutants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Modeling bacterial phenotypes using conditional knockdown mutants Dirk Schnappinger, PhD Weill Cornell Medical College

  2. Target-based antibacterial drug discovery has been difficult Payne et al (2007) Drugs for bad bugs: confronting challenges of antibacterial discovery. Nature Reviews Drug Discovery 6, 29.

  3. Target-based antibacterial drug discovery – some reasons for failure • Selection of an inappropriate target → Develop and apply a genetic approach to identify Mtb genes required for growth and survival during all phases of an infection. → Measure vulnerability of Mtb to partial inactivation specific enzymes. • Biochemical screens against purified enzymes do not select for compounds that are able to enter the bacterial cell → Engineer Mtb strains that are hypersusceptible to inhibition of a specific enzyme or pathway.

  4. Evaluating Mtb proteins / pathways as new targets for drug development: biotin metabolism • Biotin is required to synthesize several essential components of the mycobacterial cell envelope. • Transposon mutants are strongly attenuated in mice (Sassetti and Rubin).

  5. The biotin biosynthesis pathway Amiclenomycin prevents mycobacterial growth through inhibition of BioA. Crystal structure of BioA has been solved (Sacchettini).

  6. MtbDbioA

  7. MtbDbioA

  8. MtbDbioA

  9. MtbDbioA Biotin concentration in human serum: 0.1 to 3.3 nM (Hansen & Holm, Clin. Chem. 35/8, 1989) 0.01 to 0.2 nM (Hayakawa & Oizumi J Chrom 1987)

  10. MtbDbioA

  11. MtbbioA TetON

  12. Impact of silencing bioA during infections

  13. Impact of silencing bioA during infections Plus doxy Doxy day 1 to 10 Doxy day 1 to 56 Day 56 Dav 112 Day 168 Day 224

  14. Conclusions relevant to the evaluation of BioA (biotin metabolism) as a drug target Small molecules that efficiently and specifically inhibit BioA are predicted: • to be inactive in the presence of >25 nM biotin, • to be bactericidal in the absence of biotin, • to be effective during acute and chronic infections (given sufficient bioavailability), • to require months to eliminate Mtb during an infection. Correlation between chemistry and genetics will of course not be perfect.

  15. How efficient do BioA inhibitors have to be? MtbbioA TetON-1 grows without inducer in mice.

  16. Engineer Mtb strains that are hypersusceptible to inhibition of a specific enzyme or pathway

  17. Engineer Mtb strains that are hypersusceptible to inhibition of a specific enzyme or pathway bioATetON-1 M. tuberculosis

  18. Summary BioA is required for (i) growth and survival of Mtb in biotin-free liquid medium, and (ii) growth and persistence of Mtb in mice. BioA is a low vulnerability target but an otherwise “druggable” target and partial knockdown mutants might facilitate the development of BioA inhibitors with whole cell activity. Developed system with improved gene silencing activity and faster kinetics of inactivation.

  19. Weill Cornell Ehrt, Sabine Ferraras, Julian Klotzsche, Marcus Monteleone, Mercedes Odaira, Toshiko Park, SaeWoong Thanks to University of Minnesota Aldrich,Courtney Finzel, Barry Duckworth, Benjamin Shi, Ce Wilson, Daniel Novartis, Singapore Camacho, Luis Dartois, Veronique Dick, Thomas Manjunatha, Ujjini Pethe, Kevin Rao, Srini NIH/NIAID Barry, Clifton Boshoff, Helena University of Pittsburgh Flynn, JoAnne Lin, Philana Imperial College Robertson, Brian Williams, Kerstin Robert Wilkinson Young, Douglas Harvard University Rubin, Eric Wei, Jun-Rong Stanford Dolganov, Gregory Schoolnik, Gary Yonsei/Masan, Korea Cho, Ray Taek-Sun Song SBRI Rustad, Tige Sherman, David

More Related